Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121-1127.
Kyle RA, Rajkumar SV, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3-9.
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354(13):1362-1369.
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346(8):564-569.
Greenberg AJ, Vachon CM, Rajkumar SV, Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012;26(4):609-614.
Landgren O, Grideley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGuS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107(3):904-906.
Landgren O, Katzmann JA, Hsing AW et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007;82(12):1468-1473.
Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009;114(4):791-795.
Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 2009;113(25):6386-6391.
Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 2010;116(7):1056-1059.
Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ III, Colby CL et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study, Lancet 2010;375(9727):1721-1728.
12, Kyle RA, Monoclonal gammopathy of undetermined significance, Natural history in 241 cases. Am J Med 1978;64(5):814-826.
13, Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, III. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004;79(7):859-866.
14, Kristinsson SY, Björkholm M, Andersson T M L, Eloranta S, Dickman PW, Goldin LR et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009;94(12):1714-172.
Rosinol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc 2007;82(4):428-434.
Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992;81(3):391-394
Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001;86(11):1172-1179.
Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110(7):2586-2592.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ III, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812-817.
Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood 2010;116(12):2019-2025.
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009;23(9):1545-1556.
Pepe J, Petrucci MT, Nofroni I, Fassino V, Diacinti D, Romagnoli E et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 2006;134(5):485-490
Bida JP, Kyle RA, Therneau TM, Melton LJ III, Plevak MF, Larson DR et al. Disease associations with monoclonal gammopathy of undetermined significance: a populationbased study of 17, 398 patients. Mayo Clin Proc 2009;84(8):685-693.
Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA, Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004;19(1):25-30.
Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Blimark C, Mellqvist UH et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 2010;116(15):2651-2655.
Pepe J, Petrucci MT, Mascia ML, Piemonte S, Fassino V, Romagnoli E et al. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif Tissue Int 2008;82(6):418-426.
Berenson JR, Yellin O, Boccia RV, Flam M, Wong SF, Batuman O et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res 2008;14(19):6289-6295.
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies, Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010;15(3):185-195.
Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboem bolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004;15(10):1490-1494.
Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004;101(3):558-566
Cohen AL, Sarid R, The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res 2010;125(3):216-219.
Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008;112(9):3582-3586.
Kristinsson SY, Pfeiffer RM, Bjorkholm M, Goldin LR, Schulman S, Blimark C et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010;115(24):4991-4998.
Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournie B. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Joint Bone Spine 2002;69(1):62-67.
Paueksakon P, Revelo MP, Horn RG, Shappell S, Fogo AB, Monoclonal gammopathy: significance and possible causality in renal disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 42 [1], 87-95. 1-7-2003, Notes
Daoud MS, Lust JA, Kyle RA, Pittelkow MR, Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol 1999;40(4):507-535.
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGuS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113(22):5412-5417.
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM, A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113(22):5418-5422.
Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma Best Pract Res Clin Haematol 2007;20:571-96.
Blade J, Rosinol L, Cibeira MT, de Larreaa CF, Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008;22(9):1651-1657.
